Evolving global risk assessment of ocular hypertension to glaucoma

Current Opinion in Ophthalmology

Volumn 18, Issue 2, 2007, Pages 104-109

  Fechtner, Robert D ^a   Khouri, Albert S ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Glaucoma; Ocular hypertension; Risk assessment

Indexed keywords

CALCULATION; CLINICAL EXAMINATION; CORNEA THICKNESS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; EYE CARE; FAMILY HISTORY; GLAUCOMA; HIGH RISK PATIENT; HISTORY; HUMAN; INTRAOCULAR HYPERTENSION; MEDICAL LITERATURE; OPTIC NERVE; PATIENT ASSESSMENT; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RACE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; VISUAL FIELD; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

AGE FACTORS; DISEASE PROGRESSION; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OCULAR HYPERTENSION; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 33847072050     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICU.0b013e32808373a2     Document Type: Review

References (42)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-713; discussion 829-830.
2. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:714-720; discussion 829-830.
3. Friedman DS, Wilson MR, Liebmann JM, et al. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004; 138:S19-S31.
4. Quigley HA, Enger C, Katz J, et al. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol 1994; 112:644-649.
5. Martinez GS, Campbell AJ, Reinken J, Allan BC. Prevalence of ocular disease in a population study of subjects 65 years old and older. Am J Ophthalmol 1982; 94:181-189.
6. Leske MC, Connell AM, Wu SY, et al. Risk factors for open-angle glaucoma: the Barbados Eye Study. Arch Ophthalmol 1995; 113:918-924.
7. Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the Visual Impairment Project. Ophthalmology 2002; 109:1047-1051.
8. Leske MC, Nemesure B, He Q, et al. Patterns of open-angle glaucoma in the Barbados Family Study. Ophthalmology 2001; 108:1015-1022.
9. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma: the Baltimore Eye Survey. JAMA 1991; 266:369-374.
10. Friedman DS, Jampel HD, Munoz B, West SK. The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol 2006; 124:1625-1630. A recent report of significantly increased risk of OAG in an elderly population of black compared with white individuals.
11. Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001; 108:1943-1953.
12. Wolfs RC, Klaver CC, Ramrattan RS, et al. Genetic risk of primary open-angle glaucoma: population-based familial aggregation study. Arch Ophthalmol 1998; 116:1640-1645.
13. Mitchell P, Smith W, Chey T, Healey PR. Open-angle glaucoma and diabetes: the Blue Mountains eye study, Australia. Ophthalmology 1997; 104:712-718.
14. Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol 2003; 121:48-56.
15. The Advanced Glaucoma Intervention Study (AGIS): 12. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophthalmol 2002; 134:499-512.
16. Perkins ES, Phelps CD. Open angle glaucoma, ocular hypertension, low-tension glaucoma, and refraction. Arch Ophthalmol 1982; 100:1464-1467.
17. Mitchell P, Wang JJ, Hourihan F. The relationship between glaucoma and pseudoexfoliation: the Blue Mountains eye study. Arch Ophthalmol 1999; 117:1319-1324.
18. Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol 2001; 131:699-708.
19. Kass MA, Gordon MO, Hoff MR, et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals: a randomized, double-masked, long-term clinical trial. Arch Ophthalmol 1989; 107:1590-1598.
20. Schulzer M, Drance SM, Douglas GR. A comparison of treated and untreated glaucoma suspects. Ophthalmology 1991; 98:301-307.
21. Wilensky JT, Kaufman PL, Frohlichstein D, et al. Follow-up of angle-closure glaucoma suspects. Am J Ophthalmol 1993; 115:338-346.
22. Epstein DL, Krug JH Jr, Hertzmark E, et al. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 1989; 96:1460-1467.
23. Cioffi GA, Liebmann JM. Translating the OHTS results into clinical practice. J Glaucoma 2002; 11:375-377.
24. Budenz DL, Anderson DR, Feuer WJ, et al. Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. Ophthalmology 2006; 113:2137-2143.
25. Georgopoulos G, Andreanos D, Liokis N, et al. Risk factors in ocular hypertension. Eur J Ophthalmol 1997; 7:357-363.
26. Johnson CA, Keltner JL, Cello KE, et al. Baseline visual field characteristics in the Ocular Hypertension Treatment Study. Ophthalmology 2002; 109:432-437.
27. Brandt JD, Beiser JA, Kass MA, Gordon MO. Central corneal thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 2001; 108:1779-1788.
28. Medeiros FA, Sample PA, Weinreb RN. Corneal thickness measurements and visual function abnormalities in ocular hypertensive patients. Am J Ophthalmol 2003; 135:131-137.
29. Girkin CA, Kannel WB, Friedman DS, Weinreb RN. Glaucoma risk factor assessment and prevention: lessons from coronary heart disease. Am J Ophthalmol 2004; 138:S11-S18.
30. Kannel WB. Contributions of the Framingham Study to the conquest of coronary artery disease. Am J Cardiol 1988; 62:1109-1112.
31. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143-3421.
32. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
33. Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. Circulation 1998; 97:1876-1887.
34. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore Eye Survey. Arch Ophthalmol 1991; 109:1090-1095.
35. Leske MC, Wu SY, Nemesure B, Hennis A. Incident open-angle glaucoma and blood pressure. Arch Ophthalmol 2002; 120:954-959.
36. HattenhauerMG, Johnson DH, Ing HH, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998; 105:2099-2104.
37. Quigley HA, Tielsch JM, Katz J, Sommer A. Rate of progression in open-angle glaucoma estimated from cross-sectional prevalence of visual field damage. Am J Ophthalmol 1996; 122:355-363.
38. Mansberger SL. A risk calculator to determine the probability of glaucoma. J Glaucoma 2004; 13:345-347.
39. Medeiros FA, Weinreb RN, Sample PA, et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol 2005; 123:1351-1360.
40. Ocular Hypertension Treatment Study Group, European Glaucoma Prevention Study Group. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007; 114:10-19. A validated risk model from the OHTS study was developed and tested on a large population in the EGPS study. The data were presented at the American Academy of Ophthalmology meeting in 2006.
41. Mansberger SL, Cioffi GA. The probability of glaucoma from ocular hypertension determined by ophthalmologists in comparison to a risk calculator. J Glaucoma 2006; 15:426-431.
42. Weinreb RN, Friedman DS, Fechtner RD, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 2004; 138:458-467.